Cargando…

The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer

BACKGROUND: Inflammation and metabolic syndrome (MetS) may act synergistically and possibly accelerate the initiation and progression of colorectal cancer (CRC). We prospectively examined the joint effect of MetS and inflammation on the risk of CRC. METHODS: We studied 92,770 individuals from the Ka...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tong, Fan, Yali, Zhang, Qingsong, Wang, Yiming, Yao, Nan, Song, Mengmeng, Zhang, Qi, Cao, Liying, Song, Chunhua, Shi, Hanping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307555/
https://www.ncbi.nlm.nih.gov/pubmed/35715516
http://dx.doi.org/10.1007/s00011-022-01597-9
_version_ 1784752789332688896
author Liu, Tong
Fan, Yali
Zhang, Qingsong
Wang, Yiming
Yao, Nan
Song, Mengmeng
Zhang, Qi
Cao, Liying
Song, Chunhua
Shi, Hanping
author_facet Liu, Tong
Fan, Yali
Zhang, Qingsong
Wang, Yiming
Yao, Nan
Song, Mengmeng
Zhang, Qi
Cao, Liying
Song, Chunhua
Shi, Hanping
author_sort Liu, Tong
collection PubMed
description BACKGROUND: Inflammation and metabolic syndrome (MetS) may act synergistically and possibly accelerate the initiation and progression of colorectal cancer (CRC). We prospectively examined the joint effect of MetS and inflammation on the risk of CRC. METHODS: We studied 92,770 individuals from the Kailuan study. MetS was defined based on the presence of three or more of the following components. (1) high glucose: FPG > 5.6 mmol/L; (2) high blood pressure: SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; (3) high triglycerides: triglycerides > 1.69 mmol/L; (4) low HDL-C: HDL-C < 1.04 mmol/L in men or 1.29 mmol/L in women; and (5) visceral adiposity: waist circumference ≥ 85 cm in men or 80 cm in women. Inflammation was defined as hs-CRP ≥ 3 mg/L. We divided participants into four groups for the primary exposure according to the presence/absence of inflammation and presence/absence of MetS. Cox proportional hazards regression models were used to evaluate the association of MetS and/or inflammation with the risk of CRC. RESULTS: Compared with metabolically healthy noninflammatory individuals, inflammatory participants without MetS and inflammatory participants with MetS were associated with a 1.3-fold and 4.18-fold increased risk of CRC with corresponding HRs (95% CI) of 1.34 (1.09, 1.64) and 4.18 (3.11, 5.62), respectively. The combination of MetS and inflammation was associated with the highest risk of CRC in all subgroups, especially among participants who were female, in younger age, and obese. Sensitivity analyses further validated our primary findings. CONCLUSIONS: We found the combination of MetS and inflammation could significantly increase the risk of CRC. Including CRP in the diagnosis of MetS may help to identify additional high-risk participants who should be targeted for early diagnosis and prevention of CRC. Trial registration Kailuan study, ChiCTR–TNRC–11001489. Registered 24 August, 2011-Retrospectively registered, http:// www.chictr.org.cn/showprojen.aspx?proj=8050 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00011-022-01597-9.
format Online
Article
Text
id pubmed-9307555
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-93075552022-07-24 The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer Liu, Tong Fan, Yali Zhang, Qingsong Wang, Yiming Yao, Nan Song, Mengmeng Zhang, Qi Cao, Liying Song, Chunhua Shi, Hanping Inflamm Res Original Research Article BACKGROUND: Inflammation and metabolic syndrome (MetS) may act synergistically and possibly accelerate the initiation and progression of colorectal cancer (CRC). We prospectively examined the joint effect of MetS and inflammation on the risk of CRC. METHODS: We studied 92,770 individuals from the Kailuan study. MetS was defined based on the presence of three or more of the following components. (1) high glucose: FPG > 5.6 mmol/L; (2) high blood pressure: SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; (3) high triglycerides: triglycerides > 1.69 mmol/L; (4) low HDL-C: HDL-C < 1.04 mmol/L in men or 1.29 mmol/L in women; and (5) visceral adiposity: waist circumference ≥ 85 cm in men or 80 cm in women. Inflammation was defined as hs-CRP ≥ 3 mg/L. We divided participants into four groups for the primary exposure according to the presence/absence of inflammation and presence/absence of MetS. Cox proportional hazards regression models were used to evaluate the association of MetS and/or inflammation with the risk of CRC. RESULTS: Compared with metabolically healthy noninflammatory individuals, inflammatory participants without MetS and inflammatory participants with MetS were associated with a 1.3-fold and 4.18-fold increased risk of CRC with corresponding HRs (95% CI) of 1.34 (1.09, 1.64) and 4.18 (3.11, 5.62), respectively. The combination of MetS and inflammation was associated with the highest risk of CRC in all subgroups, especially among participants who were female, in younger age, and obese. Sensitivity analyses further validated our primary findings. CONCLUSIONS: We found the combination of MetS and inflammation could significantly increase the risk of CRC. Including CRP in the diagnosis of MetS may help to identify additional high-risk participants who should be targeted for early diagnosis and prevention of CRC. Trial registration Kailuan study, ChiCTR–TNRC–11001489. Registered 24 August, 2011-Retrospectively registered, http:// www.chictr.org.cn/showprojen.aspx?proj=8050 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00011-022-01597-9. Springer International Publishing 2022-06-18 2022 /pmc/articles/PMC9307555/ /pubmed/35715516 http://dx.doi.org/10.1007/s00011-022-01597-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research Article
Liu, Tong
Fan, Yali
Zhang, Qingsong
Wang, Yiming
Yao, Nan
Song, Mengmeng
Zhang, Qi
Cao, Liying
Song, Chunhua
Shi, Hanping
The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer
title The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer
title_full The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer
title_fullStr The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer
title_full_unstemmed The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer
title_short The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer
title_sort combination of metabolic syndrome and inflammation increased the risk of colorectal cancer
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307555/
https://www.ncbi.nlm.nih.gov/pubmed/35715516
http://dx.doi.org/10.1007/s00011-022-01597-9
work_keys_str_mv AT liutong thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT fanyali thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT zhangqingsong thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT wangyiming thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT yaonan thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT songmengmeng thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT zhangqi thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT caoliying thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT songchunhua thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT shihanping thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT liutong combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT fanyali combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT zhangqingsong combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT wangyiming combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT yaonan combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT songmengmeng combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT zhangqi combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT caoliying combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT songchunhua combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer
AT shihanping combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer